MAPT and Alzheimer disease: In humans, a Phase 2a safety, pharmacokinetics, and biomarker study in 13 AD patients showed that after 28 days of twice daily oral treatment, all patients had a biomarker response to the drug (CSF P-tau decreased 34%, p < 0.0001), which was well tolerated, with no drug-related adverse events [85].